PIK3CA and breast cancer: A clinical trial showed that alpelisib, a PIK3CA inhibitor, plus fulvestrant improved outcomes in PIK3CA-mutated luminal metastatic BC.61 Alpelisib is not available in Colombia; therefore, PIK3CA testing is contingent on therapy approval.